11 results about "Disease pathogenesis" patented technology

The invention discloses a Parkinson's disease animal model, a construction method and application, and relates to the field of animal genetic engineering and disease model construction. According to the model, seven mutation sites related to the human familial Parkinson's disease are introduced behind an initiation codon of a fourth exon of an endogenous SNCA gene, and the mutation sites are A18T, A29S, A30P, E46K, H50Q, G51D and A53T and have genotypes related to the human familial Parkinson's disease. The pig model shows nigra dopaminergic neuron reduction and cortical neuron reduction in the newborn period, and the core pathological process of the human Parkinson's disease can be systematically reproduced. The model can be widely applied to Parkinson's disease pathogenesis research, drug screening and cell therapy effect evaluation, and has important scientific research and preclinical application values.

Described herein are gene features that provide prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, including immune checkpoint regulators such as Programmed Death Ligand 1 (PDL-1). Using the methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers indicate disease pathogenesis, which provides opportunities for selection of treatments, including treatment regimens intended to overcome tolerance mechanisms.

Described herein are gene features for providing prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, methods and compositions for determining cancer and subtypes, including breast cancer, and provide specific and sensitive detection of biomarkers of interest. Such biomarkers indicate disease pathogenesis, which provides opportunities to select treatment, including treatment regimens intended to identify responsive candidates and overcome resistance mechanisms.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, including immune checkpoint regulators such as programmed death ligand 1 (PDL-1). Using methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at overcoming resistance mechanisms.

The invention discloses a screening method and application of an Asian human NMOSD high-pathogenicity antibody, and belongs to the technical field of autoimmune disease diagnosis and treatment. The screening method comprises the following steps: screening an Asian human NMOSD patient with poor glucocorticoid treatment prognosis, extracting serum AQP4-IgG, carrying out specific capture through M23 type AQP4 transfection cells, combining with primary astrocyte C3 inducibility verification, and screening to obtain the high-pathogenicity antibody. The antibody can mediate construction of a glucocorticoid treatment resistant NMOSD animal model, and is applied to disease pathogenic mechanism research and targeted drug screening. The antibody is screened on the basis of clinical prognosis phenotype and functional characteristics, sequence identification is not needed, the technical blank of Asian human NMOSD high-pathogenicity antibody screening is filled, and the application value is remarkable.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, Methods and compositions for determining cancer and subtypes, including breast cancer are described and specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at identifying candidates for responsiveness and overcoming resistance mechanisms.

The invention provides a free-moving mouse stomach nerve optical genetic manipulation and stomach movement synchronous recording system. The system comprises an optical genetic nerve manipulation module, a stomach movement detection module, a wireless energy supply and control module, a time synchronization module and a data acquisition and fusion module. A miniature LED light source, a bridge strain gauge sensor and a wireless energy receiving coil which are implanted in vivo are matched with an in-vitro wireless energy supply, time synchronization and data acquisition assembly, so that optical genetic activation / inhibition of gastric autonomic nerves and high-resolution capture of gastric movement signals are realized, and time alignment of the gastric autonomic nerves and the gastric movement signals is realized by outputting TTL (Transistor-Transistor Logic) pulses by virtue of a micro-control unit; according to the system, the mouse does not need to be fixed or anesthetized, the implanted component is excellent in biocompatibility, long-term continuous recording can be achieved, time synchronization is accurate, and key technical support is provided for analyzing a stomach autonomic nerve innervation mechanism, exploring the relation between stomach autonomic nerve abnormity and stomach dyskinesia, studying gastrointestinal tract disease pathogenesis and the like.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

Described herein are gene features for providing prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, methods and compositions for determining cancer and subtypes, including breast cancer, and provide specific and sensitive detection of biomarkers of interest. Such biomarkers indicate disease pathogenesis, which provides opportunities to select treatment, including treatment regimens intended to identify responsive candidates and overcome resistance mechanisms.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, Methods and compositions for determining cancer and subtypes, including breast cancer are described and specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at identifying candidates for responsiveness and overcoming resistance mechanisms.